Harvard Bioscience Dirección

Dirección controles de criterios 1/4

El CEO de Harvard Bioscience's es Jim Green , nombrado en Jul 2019, tiene una permanencia de 4.75 años. compensación anual total es $2.39M, compuesta por 24.5% salario y 75.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.33% de las acciones de la empresa, por valor de €6.46M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 6.5 años, respectivamente.

Información clave

Jim Green

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	24.5%
Permanencia del CEO	4.8yrs
Participación del CEO	4.3%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	6.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Green en comparación con los beneficios de Harvard Bioscience?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$586k	-US$3m
Sep 30 2023	n/a	n/a	-US$3m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$2m	US$574k	-US$10m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$3m	US$574k	-US$288k
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$3m	US$574k	-US$8m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$3m	US$265k	-US$5m
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	US$432k
Mar 31 2019	n/a	n/a	-US$819k
Dec 31 2018	US$153k	n/a	-US$4m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$7m
Dec 31 2017	US$129k	n/a	-US$2m

Compensación vs. Mercado: La compensación total de Jim($USD2.39M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.27K).

Compensación vs. Ingresos: La compensación de Jim ha aumentado mientras la empresa no es rentable.

CEO

Jim Green (65 yo)

4.8yrs

Permanencia

US$2,392,240

Compensación

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Green	President	4.8yrs	US$2.39m	4.33% $ 6.7m
Jennifer Cote	CFO & Treasurer	1.3yrs	US$571.27k	0.097% $ 150.6k
David Balcom	Senior Vice President of Operations	1.8yrs	sin datos	sin datos
John Fry	Chief Legal Counsel & Corporation Secretary	1.8yrs	sin datos	sin datos
Ryan Wallace	Senior Vice President of Global Sales	less than a year	sin datos	sin datos
Lori Packer	Vice President of Global People Operations	no data	sin datos	sin datos

1.8yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HBI no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Green	President	9.1yrs	US$2.39m	4.33% $ 6.7m
Alan Edrick	Independent Director	4.7yrs	US$213.09k	0.47% $ 723.9k
Bertrand Loy	Lead Independent Director	9.5yrs	US$223.06k	1.08% $ 1.7m
Thomas Loewald	Independent Director	6.6yrs	US$205.45k	0.52% $ 800.4k
Katherine Eade	Independent Director	6.6yrs	US$198.09k	0.55% $ 856.9k

6.6yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de HBI se considera experimentada (6.5 años de antigüedad promedio).

Harvard Bioscience Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

President recently bought €101k worth of stock

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

President recently bought €100k worth of stock

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought €72k worth of stock

Recent updates

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.081 loss per share (vs US$0.23 loss in FY 2022)

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Third quarter 2023 earnings released: US$0.029 loss per share (vs US$0.082 loss in 3Q 2022)

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President recently bought €101k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.023 loss per share (vs US$0.059 profit in 2Q 2022)

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 24% undervalued after recent price drop

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

Now 22% undervalued

Now 20% undervalued

Now 21% undervalued

President recently bought €100k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.007 loss in FY 2021)

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought €72k worth of stock

Forecast breakeven date pushed back to 2024

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

President recently bought €125k worth of stock

Forecast breakeven date pushed back to 2023

Second quarter 2022 earnings released: EPS: US$0.059 (vs US$0.01 loss in 2Q 2021)

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought €107k worth of stock

President recently bought €140k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Forecast to breakeven in 2021

President recently sold €329k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Harvard Bioscience, Inc. Files A Motion to Vacate the Suffolk Superior Court’S Order Allowing Plaintiff’S Motion for Sanctions

Independent Director has left the company

Harvard Bioscience, Inc. Provides Financial Guidance for 2021

First quarter 2021 earnings released: US$0.017 loss per share (vs US$0.12 loss in 1Q 2020)

President recently sold €175k worth of stock

New 90-day high: €4.30

Full year 2020 earnings released: US$0.20 loss per share (vs US$0.12 loss in FY 2019)

Revenue beats expectations

Harvard Bioscience, Inc. to Report Q4, 2020 Results on Mar 10, 2021

New 90-day high: €3.76

New 90-day high: €3.44

New 90-day high: €3.24